Literature DB >> 213722

Endometrial cancer and estrogen use. Report of a large case-control study.

C M Antunes, P D Strolley, N B Rosenshein, J L Davies, J A Tonascia, C Brown, L Burnett, A Rutledge, M Pokempner, R Garcia.   

Abstract

Our case-control study of the relation between estrogen use and endometrial cancer involved 451 cases and 888 controls. The overall risk of endometrial carcinoma was sixfold for estrogen users as compared with nonusers; long-term users (greater than five years) had a 15-fold risk. Excess risk was present for both diethylstilberstrol and conjugated estrogens. The risk associated with cyclic use was as great as that for continuous use. Increased risk was associated with estrogen use for all histologic grades of the tumor. The risk of advanced-stage carcinoma was fourfold for estrogen users, but rhe confidence interval was wide, and this question requires further study. Finally, this investigation contradicts the speculation that the association between this cancer and estrogen use can be explained by swifter diagnosis for estrogen users, misclassification of estrogen-related hyperplasia or treatment of early symptoms of the tumor with estrogen.

Entities:  

Keywords:  Biology; Cancer; Contraceptive Agents, Estrogen; Diethylstilbestrol--administraction and dosage; Diethylstilbestrol--side effects; Diseases; Endocrine System; Endometrial Cancer--etiology; Estrogens--administraction and dosage; Estrogens--side effects; Examinations And Diagnoses; Hormones; Neoplasms; Oral Contraceptives; Physiology; Research Methodology; Retrospective Studies; Studies

Mesh:

Substances:

Year:  1979        PMID: 213722     DOI: 10.1056/NEJM197901043000103

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  42 in total

1.  Interval estimation of the attributable risk in case-control studies with matched pairs.

Authors:  K J Lui
Journal:  J Epidemiol Community Health       Date:  2001-12       Impact factor: 3.710

Review 2.  Hormone replacement therapy and breast cancer, endometrial cancer and cardiovascular disease: risks and benefits.

Authors:  M K Goddard
Journal:  Br J Gen Pract       Date:  1992-03       Impact factor: 5.386

Review 3.  [The role of progestins].

Authors:  H I Wyss
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

4.  Loss of inhibitory insulin receptor substrate-1 phosphorylation is an early event in mammalian target of rapamycin-dependent endometrial hyperplasia and carcinoma.

Authors:  Adrienne S McCampbell; Heather A Harris; Judy S Crabtree; Richard C Winneker; Cheryl L Walker; Russell R Broaddus
Journal:  Cancer Prev Res (Phila)       Date:  2010-02-23

5.  Screening for endometrial cancer.

Authors:  J A Nisker
Journal:  Can Fam Physician       Date:  1983-05       Impact factor: 3.275

Review 6.  Megatrials of hormonal replacement therapy.

Authors:  B G Wren
Journal:  Drugs Aging       Date:  1998-05       Impact factor: 3.923

7.  Prescribing estrogen during menopause: physician survey of practices in 1974 and 1981.

Authors:  B H Pasley; S J Standfast; S H Katz
Journal:  Public Health Rep       Date:  1984 Jul-Aug       Impact factor: 2.792

Review 8.  Transdermal estradiol/norethisterone. A review of its pharmacological properties and clinical use in postmenopausal women.

Authors:  L R Wiseman; D McTavish
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

9.  Involution of latent endometrial precancers by hormonal and nonhormonal mechanisms.

Authors:  Ming-Chieh Lin; Kyla A Burkholder; Akila N Viswanathan; Donna Neuberg; George L Mutter
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

10.  Lewis rats of the inbred strain LEW/Han: life expectancy, spectrum and incidence of spontaneous neoplasms.

Authors:  A Baum; G Pohlmeyer; K G Rapp; F Deerberg
Journal:  Exp Toxicol Pathol       Date:  1995-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.